Biotechnology company Synlogic (NASDAQ: SYBX) shares are rallying on Monday after the company its SYNB1891 drug has advanced into the combination therapy stage of the ongoing Phase 1 trial.
The Massachusetts based company’s investigational drug is used for the treatment of solid tumours and lymphoma. It is being advanced due to acceptable safety doses evaluated to date, intratumoral injection feasibility, successful escalation to clinically relevant dose levels, and evidence of target engagement and immune system upregulation.
“Synlogic is designing Synthetic Biotic medicines that work uniquely inside the tumour microenvironment, boosting the patient’s immune response and promoting the body’s ability to detect and destroy cancer cells.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
“The interim results of our monotherapy cohorts suggest SYNB1891 is working as designed, upregulating the immune system in the tumour microenvironment via the STING pathway,” said Synlogic’s President and CEO, Aoife Brennan.
The company said that to date its study results have shown SYNB1891 is safe and well-tolerated at the current evaluated dose levels, and treatment with the drug “demonstrates activation of the STING pathway and target engagement.”
Synlogic’s stock price is up 72% premarket at $3.95 after closing Friday’s session at $2.21 per share.
PEOPLE WHO READ THIS ALSO VIEWED:
